JANUX THERAPEUTICS INC (JANX)
US47103J1051 - Common Stock
Why Janux Therapeutics Crushed the Market Today
Janux Therapeutics Announces Proposed Public Offering
Notable Tuesday Option Activity: ALK, JANX, AMKR
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Let's have a look at the gap up and gap down stocks in today's session.
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Monday's after hours session: top gainers and losers
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
JANX Crosses Below Key Moving Average Level
Oversold Conditions For Janux Therapeutics (JANX)
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the second quarter o...
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Commit To Purchase Janux Therapeutics At $25, Earn 17.6% Annualized Using Options
Janux Therapeutics Announces Updates to Board of Directors
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the first quarter of...
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Janux Therapeutics (JANX) stock has gone parabolic: what next?
Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.45 billion. Analysts are optimistic about Janux Janux Therapeutics […]
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden.